🚀 ProPicks AI Hits +34.9% Return!Read Now

REFILE-S.African businessman Tannenbaum denies $1.2 bln fraud

Published 06/12/2009, 04:20 AM
Updated 06/12/2009, 04:32 AM

* Says found himself in financial predicament

* Says time will show had defrauded no-one

(corects spelling of Tannenbaum in paragraph 4)

By Marius Bosch

JOHANNESBURG, June 12 (Reuters) - South African businessman Barry Tannenbaum, accused of defrauding hundreds of investors in what may be the country's biggest corporate fraud, denied any wrongdoing and blamed the economic crisis for his company's woes.

"As has happened with other companies that have from time to time found themselves in a financial predicament, particularly in the present climate, I have found myself in such a situation," he said in an e-mailed statement on Friday.

Tannenbaum, who lives in Australia, said he had defrauded no-one and described accusations against him as wild allegations, speculation and conjecture.

"In short, the hype at this stage is such that whatever I say, will be disbelieved. Time will demonstrate that I have defrauded no-one," Tannenbaum said.

Lawyers and investigators said on Thursday hundreds of investors, including top businessmen from South Africa, the United States, Germany and Australia, were affected.

Tannenbaum was said to have lured investors with the promise of 200 percent annual returns linked to pharmaceutical imports and was accused of forging AIDS drug orders to give reassurance when money started to dry up.

The case could rank as South Africa's biggest corporate fraud and has shocked the country's business community, known for its conservative approach to risk and investment.

The South African Reserve Bank said it had become aware of the issue this week after complaints from investors who were no longer receiving their returns and would check if exchange control and banking rules had been broken.

Tannenbaum operated through his Frankel International and Frankel Chemical Corp companies and says in brochures his father was a founder of South Africa's No. 2 pharmaceuticals firm, Adcock Ingram. Adcock said it was his grandfather.

Documents posted on the Internet by Investigator Specialised Services Group, a private law enforcement agency hired by investors to look into Tannenbaum, include what it said are forged purchase orders from Africa's biggest generic drugmaker, Aspen, which Tannenbaum allegedly used to show investors funds were coming soon.

Both Adcock and Aspen confirmed they had bought small amounts of supplies from Frankel, but said the purchase documents, including some involving life-prolonging anti-retroviral AIDS drugs, were fake. (Editing by David Holmes)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.